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CLINICAL INVESTIGATION
Increased expression of a brain/embryo-type myosin heavy chain
isoform (MIIB2) in mesangial proliferative glomerulonephritis
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Increased expression of a brain/embryo-type myosin heavy chain iso-
form (MIIB2) in mesangial proliferative glomerulonephritis. Prolifera-
tion of mesangial cells is frequently found in glomerulonephritis, such as
IgA glomerulonephritis. Recent reports suggest that a brain/embryo-type
myosin isoform (MIIB2) is involved in cell proliferation. We have studied
the expression of MIIB2 in renal biopsy samples from patients with
various renal diseases and in the renal tissues from the rat model of
mesangial proliferative glomerulonephritis induced with anti-Thy 1.1
antibody. Immunohistochemical analysis of the biopsy samples using an
anti-brain-type myosin heavy chain-specific monoclonal antibody (HBM1)
indicated that 92% of the samples from patients with IgA glomerulone-
phritis contained a significant population of mesangial cells that reacted
with the antibody. Most of the samples from patients with other types of
proliferative glomerular diseases also contained HBM1-reactive mesan-
gial cells, while none of the samples from patients with non-proliferative
glomerular diseases contained a significant population of HBM1-reactive
mesangial cells. The expression of a brain/embryo-type myosin heavy
chain isoform (MIIB2) in the mesangial cells began at five days after
injection of anti-Thy 1.1 antibody and peaked at the tenth day. On the
other hand, the expression of the proliferating cell nuclear antigen in the
mesangial cells was induced at two days after injection of anti-Thy 1.1
antibody and was maximal at the fourth day. These results indicate that
the expression of the MIIB2 isoform by mesangial cells is accelerated in
proliferative glomerulonephritis and suggest that the myosin isoform is
involved in the phenotypic transformations of the glomerular tissues
rather than in the cell proliferation.
Mesangial cells are recognized as myofibroblasts because of
several features shared with vascular smooth muscle cells and
fibroblasts [1]. It has been shown that post-confluent rat mesangial
cells in primary culture express three distinct myosin heavy chain
(MHC) isoforms, a major MHC of 196 kDa and two minor MHCs
of 204 and 200 kDa [21, as in cultured rat aortic smooth muscle
cells [3, 1. These 196, 204 and 200 kDa MHCs were shown to be
the nonmuscle-type isoform (MIIA) and the smooth muscle-type
isoforms, SM1 and SM2, respectively [2]. It has also been shown
that the levels of the smooth muscle-type MHC isoforms relative
to that of the nonmuscle isoform further decrease in long phase
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cultures of the mesangial cells [1], as observed for the cultured
aortic smooth muscle cells [3, 41.
Brain tissues contain at least three nonmuscle-type MHC
isoforms, two brain-type MHCs of 200 and 198 kDa (brain-
specific-type and brain/embryo-type MHCs, M1IB1 or NM1 and
MIIB2 or NM2, respectively) and a non-muscle-type MHC of 196
kDa (MIIA or NM3) [5—7]. The MIIB1 is likely to be an
alternatively spliced product of the MIIB2 gene with an inserted
sequence of about 2 kDa in the head region [8, 9]. Whereas the
M1IB1 isoform is expressed almost exclusively in the brain,
especially in the cerebellum, the MIIB2 (brain/embryo-type)
isoform is also expressed in small amounts in other limited tissues
such as kidney and adrenal, and in many fetal and neonatal tissues
[5—7, 10, 11]. Recent studies also indicate that the neointimas of
atherosclerotic arteries contain an increased concentration of the
MIIB2 isoform [12, 131. These results appear to suggest that
expression of the MIIB2 isoform is accelerated in actively prolif-
erating tissues and that the isoform is involved in the proliferation
and/or phenotypic transformations of the tissues.
One of the central features of many glomerular diseases is the
proliferation of the mesangial cells [14—16]. Concomitantly with
the cellular proliferation, these cells are also known to undergo a
variety of phenotypic changes as characterized by the changes in
cell morphology, expression of a-smooth muscle actin, increased
secretion of extracellular matrix components and increased re-
lease of proteolytic enzymes and inflammatory mediators [14—18].
While at least three distinct growth factors, PDGF, bFGF and
TGF-13, have been shown to be involved in the proliferation and
phenotypic transformations [16], the mechanisms that underly the
changes are not elucidated. In the present study, to examine
whether the proliferation and transformation of the mesangial
cells involve the changes in the level of the brain/embryo-type
myosin isoform, we have studied the expression of the brain/
embryonic myosin isoform MIIB2 in the renal biopsy specimens of
patients with a variety of renal diseases and in the renal tissues
from the rat model of mesangial proliferative glomerulonephritis
(UN) induced with anti-Thy 1.1 antibody [19—21].
Methods
Patients and tissue samples
Tissue samples were obtained by percutaneous renal biopsy of
36 patients with renal diseases with ages of 14 to 75in Wakayama
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Table 1. Clinical data on patients with renal diseases and expression of brain-type MHC in mesangial cells of the biopsy specimens
Age Sex Onset Macrohematuria Hypertension
Consistent
proteinuria Histology Clinical diagnosis HBM1
Mesangial cell
hypercellularityb
45 M 42 - - + IgA GN CGN + +
36 F 35 + — + IgA GN CGN + +
45 F 43 -t- — + IgA GN CGN + 2+
14 M 14 + - IgAGN CGN + +
51 F 49 — — + IgA GN CGN + +
45 M 45 - - + IgA GN CGN + +
47 F 26 — + + IgA GN CGN + +
71 M 51 - + + IgAGN CGN + -
44 F 44 -I- — + IgA GN CGN + +
46 M 42 - - + IgA GN CGN + +
29 M 27 — - + IgA GN CGN + +
21 M 16 - - + IgAGN CGN + +
29 F 21 - - + JgA GN CGN - +
23 F 23 — — — focal proliferative GN Sjogren syndrome
21 M 21 — — — acute tubular necrosis acute renal failure — —
28 F 15 - - MGA CGN - -
60 M 40 — — + FGS CGN — —
15 F 8 — — + lupus nephritis SLE + +
56 F 56 — — + renal amyloidosis nephrotic syndrome — —
21 F 15 — — + MGN CGN + +
37 F 32 — + + lupus nephritis SLE, nephrotic syndrome
75 M 74 — — + renal amyloidosis Amyloidosis — —
69 M 68 — + + MGN nephrotic syndrome — —
54 M 54 — — + MGN nephrotic syndrome + +
59 F 58 — — + MGN CGN + +
59 F 45 — + + FGO CGN — —
26 M 26 — — + MGA nephrotic syndrome — —
33 F 26 - - + MGA CON - -
45 F 43 — — + focal proliferative GN CGN
25 F 17 - - - MGA CGN - -
65 F 60 - - + MGN CGN - -
40 F 40 — — + MGA nephrotic syndrome — —
55 M 42 - - + MGN CGN - -
22 F 21 + - - MGA CGN - -
45 F 40 - + MGN CON - -
28 F 27 — — + MGA nephrotic syndrome — —
Abbreviations are: IgA GN, IgA glomerulonephritis; MGA, minor glomerular abnormalities; FOS, focal glomerular sclerosis; MGN, membranous
glomerulonephritis; FGO, focal glomerular obsolescence; CGN, chronic glomerulonephritis; SLE, systemic lupus erythematosus.
a The intensity of immunofluorescence was graded as negative (—), trace (±), and positive (+)b The grading of mesangial cell hypercellularity was divided into four grades as negative (—), mild (+), moderate (2+) and severe (3+)
Medical College Hospital and the affilated hospitals and em-
ployed for histological, immunohistochemical, and immunofluo-
rescence studies. The 13 patients were diagnosed as IgA glomer-
ulonephritis (GN) and the other 23 patients were affected by other
types of renal diseases, as listed in Table 1. Renal tissues were also
obtained from patients with renal carcinoma (N = 3) or renovas-
cular hypertension (N = 1) by surgical operation, and the
peripheral normal tissues were employed as the control.
Induction of nephritis in rats by anti-Thy 1.1 antibody
Female Wistar rats (7 weeks old) were injected intravenously
with 100 p1 of ascites fluid containing anti-rat Thy 1.1 monoclonal
antibody (MRC OX-7) (CEDARLANE, Canada) [19—21]. The
kidneys were removed at multiple time points ranging from one
day to four weeks each time from the four rats. These kidneys
were donated for the histological and immunohistological studies
and for the preparation of glomeruli [22].
Monoclonal anti-myosin antibodies
BBM4 (1gM), which reacted efficiently with every type of
smooth muscle and nonmuscle MHC isoforms but not with
skeletal or cardiac MHC isoform, was obtained by immunizing
mice with purified bovine cerebrum myosin as described previ-
ously [5]. HBM1 (IgGi) and HBM3 (IgGi) which were specific
for brain-type and nonmuscle-type MHC isoforms, respectively,
were produced by immunizing mice with purified human cere-
brum myosin as described previously [6]. Monoclonal anti-SM1
and anti-SM2 antibodies were generous gifts from Yamasa Shoyu
Co. [12, 13].
Histological studies
The biopsy specimens were cut into 4 thin sections and
stained with hematoxylin and eosin (HE), periodic acid-Schiff
(PAS), periodic acid-methenamine silver (PAM) or Masson-
trichrome to characterize the tissues. The extent of mesangial cell
hypercellularity was graded as follows; negative (—), mild (+),
moderate (2+) and severe (3+).
Immunofluorescence studies
Renal tissue samples were quickly frozen in dry ice and acetone,
embedded in OCT (Miles Scientific) and then sectioned at a
thickness of 2 u by a cryostat. The sections were rinsed three times
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Fig. 1. Immunoblot analysis of MHC isofbrms in crude extra cts from human
cerebrum, kidney and aorta. High-salt/Mg-ATP extracts (30 jsg protein!
lane) from human cerebrum (Cer), kidney (Kid) and aorta (Ao) were
subjected to SDS-PAGE and immunoblotting with (A) anti-smooth mus-
cle and nonmuscle MHC antibody BBM4, (B) anti-brain-type MHC
antibody HBMI or (C) anti-nonmuscle MHC antibody. Abbreviations are:
M1IB1, brain-specific-type MHC; MIIB2, brain!embryo-type MHC;
MIIA, nonmuscle MHC; SM1, smooth muscle MHC-l; SM2, smooth
muscle MHC-2.
in 10 m phosphate-buffered saline (pH 7.4) (PBS) each time for
15 minutes, incubated with either FITC-labeled polyclonal anti-
bodies against human IgA, IgO, 1gM, fibrinogen (Cappel), Clq, or
C3c (DAKO) for one hour at room temperature, rinsed three
times in PBS each time for 30 minutes, and then mounted in
glycerin. For analysis of brain-type myosin, the thin sections were
incubated with HBM1 (10 jxg/ml) for four hours at 4°C, washed
three times in PBS each time for 10 minutes and then incubated
for one hour with fluorescein-conjugated goat anti-mouse IgG
(Cappel) which was preadsorbed with normal human serum. The
intensity of immunofluorescence was graded as negative (—),
trace (±) or positive (+).
Immunohistochemical staining
Frozen samples were cut into a thickness of 2 p. and placed on
silanized slides. The samples were incubated with 3% hydrogen
peroxide for five minutes at room temperature to inactivate
endogenous peroxidase activity and then incubated with 3%
normal rabbit serum to block the nonspecific protein binding sites. Fig. 2. Immunofluorescence and histochemical examination of normal its-
The sample sections were incubated with HBM1(2 p.gIml) for one sue specimens from control kidney. (A) Immunofluorescence staining with
hour at room temperature in a moist chamber. The sections were HBM1 indicates that the tissue contains a small level of brain-type MHC
incubated with a biotin-conjugated rabbit anti-mouse IgG, 1gM in the tubulointerstitial areas but not appreciably in the mesangial areas
and IgA (NICHIREI) as the second antibody and then with (X200). (B) Immunohistochemical staining with HBM1 indicates that theimmunostains are associated almost only with the tubular areas (X100).
streptoavidin-horseradish peroxidase conjugate (NICHIREI). For (C) Examination by light microscopy indicates that the glomeruli are
visualizing the reaction products, the sections were incubated with morphologically normal (PAS stain, X 100).
3-amino-9-ethylcarbazolc, a substrate for the peroxidase. Prolif-
erating cell nuclear antigen (PCNA) was stained with a monoclo-
nal antibody (PC 10) specific for PCNA (DAKO) [23, 24]. numbers of the total and PCNA-positive nuclei in more than ten
Counter-staining of the sections was performed with hematoxylin. glomeruli in photomicrographs. Macrophage infiltration into gIn-
The index of PCNA expression was determined by counting the meruli was analyzed by immunohistochemical staining CD68
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Fig. 3. Immunofluorescence and histochemical examination af a biopsy
specimen from a patient with IgA GN. (A) Immunofluorescence staining
with HBM1 indicates that a brain-type MHC is localized mostly in the
mesangial areas and slightly in the tubulointerstitial areas as well (X400).
(B) Immunohistochemical staining with HBM1 demonstrates that the
immunostains are present in both the glomeruli and tubular areas. The
immunostains are mainly in the mesangial region (B-I, X 100; B-2, X 400).
(C) Immunofluorescence staining with anti-IgA antibody reveals large
amounts of deposits of IgA in the mesangial areas (X400). (D) Light
microscupy of the tissue specimen indicates enlargement of the mesangial
area and a mild degree of cellular proliferation (PAS stain, X 100).
(DAKO) [25]. The renal tissues of rats were incuhated with
biotinylated 1-IBM1 and then with the streptoavidin-horseradish
peroxidase conjugate.
Extraction of myosin from tissues
Tissue samples from human kidney, brain and aorta and the rat
glomerular samples were homogenized in a large volume of a
low-salt solution containing 10 mrvi imidazole-HC1 (pH 7.0), 5 mM
ethylene glycol bis(f3-aminoethylether)-N, N, N', N'-tetraacetic
acid (EUTA), 5 mM EDTA, 5 mat 2-mercaptoethanol, 1 mM
phenylmethylsulfonyl fluoride, 1 mat benzamidine-HC1 and each
0.1 mglml of pepstatin A, leupeptin, aprotinin, and soybean
trypsin inhibitor [5, 6]. The homogenates were centrifuged for 10
minutes at 15,000 )< g and the supernatants were discarded. The
pellets were extracted with a 25 mat Tris-HCI (pH 7.5) buffer
containing 0.3 M NaC1, 10 mat MgCI2, 10 mat ATP, 1 mat EGTA,
5 mat 2-mercaptoethanol and the protease inhibitors, and the
extracts (high-salt/Mg-ATP extracts) were donated for MHC
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analysis. Human aorta was homogenized with the low-salt solution
containing 1% Triton X-100.
Immunoblotting
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) was carried out as described by Laemmli [261. The
polypeptides separated in the gels were transferred onto polyvi-
nylidene difluoride (PVDF) membrane sheets (Millipore) and
then blotted with monoclonal anti-myosin antibodies. The pri-
mary antibodies bound to the membrane sheets were detected
with biotin-conjugated anti-mouse IgG or 1gM (CALTAG) fol-
lowed by streptoavidin-horseradish peroxidase conjugate (Amer-
sham) and 4-chloro-1-naphtol [5, 6].
Enzyme-linked immunosorbent assay (ELISA)
HBM1-coated 96-well plates were prepared by incubating
overnight at 4°C with 100 1d/well of HBM1 solution (10 g!ml in
10 mM phosphate buffered saline, pH 7.4) and blocked with 0.3%
gelatin in 10 mrvt Tris-HC1, pH 7.4, and 0.15 M NaC1. Crude
myosin extracts from rat glomeruli (10 j.g protein in 100 p1 of 10
m Tris-HC1, pH 7.4, containing 0.5 M NaCI, 0.3% gelatin and
0.05% Tween-20) were incubated on the HMB1-coated plates for
one hour at room temperature. The myosins bound to HBM1
were detected by using biotin-conjugated BBM4 as a detector
antibody followed by avidin-horseradish peroxidase and o-phen-
ylenediamine as reagents for color development. The bound
myosins were calibrated with purified human brain myosin as a
standard.
Statistical analysis
The relationship between the degree of hypercellularity of the
mesangial cells and the intensity of staining by HBMI were
assessed by a chi-squared test. Significance was taken at the level
of P < 0.05.
Results
MHC isoforms in normal renal tissues
When crude extracts from human cerebrum, kidney and aorta
were subjected to SDS-PAGE and immunoblotting with a mono-
clonal antibody BBM4, which was able to react with various types
of smooth muscle and nonmuscle MHCs [5], both kidney and
aortic extracts gave four bands at the positions of 204, 200, 198
and 196 kDa, while the cerebral extracts gave three bands at the
positions of 200, 198 and 196 kDa (Fig. 1A). When these extracts
were blotted with a brain-type MHC-specific monoclonal antibody
HBM1, the cerebral extracts gave two bands at the positions of
200 and 198 kDa (M1IB1 and MIIB2, respectively), while both
kidney and aortic extracts gave only one band at the position of
198 kDa (MIIB2) (Fig. 1B). The 196 kDa MHC bands in all of the
extracts were also recognized by a nonmuscle MHC-specific
monoclonal antibody HBM3, and the kidney extract appeared to
contain a much higher proportion of this MHC than the extracts
from the cerebrum and aorta (Fig. 1C). The 204 kDa MHC bands
in the kidney and aortic extracts were also recognized by a
monoclonal antibody specific to smooth muscle MHC-1 (SM1)
[13], while the 200 kDa MHCs in both extracts reacted with a
smooth muscle MHC-2 (5M2)-specific monoclonal antibody [13],
while the concentration of this 200 kDa band in the kidney
extracts was very low (not shown). These results indicate that
normal human renal tissues contain at least four distinct MHC
isoforms, one nonmuscle MHC isoform (MIIA), one brain!
embryo-type MHC isoform (MIIB2) and two smooth muscle
MHC isoforms (SM1 and SM2), although the concentration of
SM2 is very low compared to those of the other isoforms. It was
also evident that normal kidney did not contain an appreciable
concentration of M1IB1, a brain-specific MHC isoform.
Immuno-histochemical analysis of brain-type MHC in renal tissues
from patients with renal diseases
When normal renal tissue samples from a patients with carci-
noma or renovascular hypertension were stained with HBM1 and
fluorescent second antibody, the tissues contained a significant
population of weakly fluorescent cells in the tubular areas, while
the glomerular areas did not apprear to contain an appreciable
population of fluorescent cells (Fig. 2A). Immunohistochemical
staining with HBM1 and peroxidase-conjugated second antibody
also indicated that only the tubular cells were reactive with HBM1
(Fig. 2B). The glomeruli in the same tissue sample had an normal
morphology under the light microscope (Fig. 2C). On the other
hand, on immunofluorescence staining with HBM1 of a renal
tissue specimen from a patient with IgA GN, the glomerular areas
contained strongly fluorescent cells, while the tubular areas
contained only weakly fluorescent cells as in the normal tissues
(Fig. 3A). Immunohistochemical staining of the specimen with
HBM1 indicated that most of the immuno-reactive materials in
the glomeruli were associated with the mesangial cells (Fig. 3B).
In these tissues, a considerable amount of IgA was deposited in
the mesangial areas (Fig. 3C), and the mesangial cells appeared to
be enlarged (Fig. 3D). These results suggested that the glomeruli
from a patient with IgA ON contain an increased concentration of
a brain-type MHC isoform in the mesangial areas, while the
concentration of the isoform in the tubular areas was low as in the
normal tissues. In order to examine whether the expression of the
brain-type MHC isoform is increased in the glomeruli of every
patient with IgA GN or not, as well as to examine whether the
increased expression of the MHC isoform is specific to IgA GN or
not, biopsy specimens from other 35 patients with various types of
renal diseases were analyzed by the same immunofluorescence
staining method as described above. The renal tissue specimens
from the 12 patients (92%) out of the 13 patients with IgA GN
were found to be highly reactive with HBM1 (Table 1), and large
portions of the fluorescent antibody were located in the glomer-
ular cells. On the other hand, when renal tissue specimens from
the other 23 patients with different types of renal diseases were
examined, the specimens from the 7 patients (31%) contained a
significant population of HBM1-reactive mesangial cells. The
specimens from the four patients with apparently enlarged mes-
angial areas were highly reactive with the antibody, while those
from the other three patients with only slightly enlarged mesangial
areas were only weakly reactive with the antibody (Table 1). The
four patients with lupus nephritis, focal proliferative GN in
proliferative renal diseases were accompanied by very mild mes-
angial cell proliferation, and the renal specimens from these
patients were not strongly reactive with HBM-1. None of the
specimens from the other 16 patients with non-proliferative renal
diseases appeared to contain a significant population of HBM1-
reactive mesangial cells in the glomeruli. But mild mesangial cell
proliferation occurred exceptionally in three patients out of the
Kishino ci' al: Brain/embiyo-type myosin heavy chain in GN 1355
seven patients with membranous nephropathy. The specimens
from the three patients were reactive with HBM-1. Thus, the level
of a brain-type MHC was high in the mesangial cells of prolifer-
ative GN but was low in the glomeruli of non-proliferative renal
diseases. A statistical analysis indicated that a significantly positive
correlation (P < 0.05) existed between the mesangial hypercellu-
larity and the level of HBM1-reactive MHC isoform in the
glomeruli. On the other hand, it was found that most of the
HBM1-reactive glomeruli did not express a significant level of the
proliferative cell nuclear antigen (PCNA), a specific marker for
the cell in S-phase of cell division [23, 24] (not shown). It was
unlikely, therefore, that the HBM 1-positive glomerular cells were
in an actively proliferating state, but these cells were likely to be
in a post-proliferated. An immunohistochemical analysis of the
renal specimens using an antibody against anti-CD68, a specific
marker for macrophage [25], revealed that none of the HBMI -
reactive glomeruli contain an appreciable level of the antigen,
indicating that infiltration of macrophages was not significant (not
shown). Furthermore, the expression of the brain-type MHC
isoform in mesangial cells did not appear to be affected by other
factors such as age, sex, age of onset of the disease, macroscopic
hematuria, high blood pressure or proteinuria (Table 1).
Expression of MIIB2 isoform in rat anti-Thy 1.1-induced GN
To examine the relationship between the development of
proliferative GN and the expression of the brain-type MHC
isoform, experimental GN was induced in rats by injecting anti-
Thy 1.1 antibody [19—21], and the time course of the changes in
the expression of the brain-type MHC in the renal tissues was
analyzed. Histological examination of the renal tissues from the
Thy 1.1 injected rats indicated that mesangiolysis took place in as
early as one day after injection of the antibody and was then
followed by proliferation of the cells (Fig. 4), as reported previ-
ously [19—21]. Consistently with the morphological changes, the
renal tissues began to express PCNA at two days after injection of
the antibody and continued to express increasing quantity of
PCNA up to four to five days and then ceased to express the
protein thereafter (Fig. 5). Immunohistochemical analysis using
HBM1 of the renal tissues indicated that the control tissues did
not contain significant number of HBM1-positive cells in the
glomeruli (Fig. 6A). The Thy 1.1-injected rats appeared to express
the brain-type MHC isoform in the mesangial areas at about five
days after injection of the antibody and to continue to express
increasing quantity of the isoform up to about the tenth day (Fig.
6B, C). To identify the isoform of MHC expressed in the
glomeruli, rather than in the whole renal tissues, as well as to
quantify the MHC isoform, the glomeruli were isolated from the
rat kidneys, and the extracts were subjected to SDS-PAGE and
immunoblotting with HBM1 (Fig. 7). Whereas the glomeruli from
control rats appeared to contain almost only one MHC isoform
(MIIA), those from Thy 1.1-injected rats contained increased
concentrations of two MHC isoforms, MIIA and MIIB2. These
extracts again did not appear to contain an appreciable concen-
tration of the brain-specific MHC isoform M1IB1. Quantitative
analysis of the MIIB2 isoform by ELISA indicated that the level
of MIIB2 began to increase at the fifth day and peaked at the
tenth day and then declined gradually (Fig. 8). The level of MIIB2
in the glomeruli at the tenth day was more than four times higher
than that of the control. The peak of the expression of MIIB2 thus
Fig. 4. Morphological changes of rat glomendi after injection of anti-Thy 1.1
antibody. Rats were injected with anti-Thy 1.1 antibody and the kidneys
were removed at the indicated days. The tissues specimens were stained
with PAS and examined under a light microscope. Compared to control
rat glomeruli (A, x 100), the glomerular cellularity is reduced on one day
after injection of anti-Thy 1.1 (B, X 100). The mesangial cells are
markedly proliferated at five days after injection of anti-Thy 1.1 (C, x
100).
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Fig. 5. Anti-Thy 1.1-induced glomerular cell proliferation as detected by
immunolabeling with PCNA. Rats were injected with anti-Thy 1.1 antibody,
and the kidneys were removed at the indicated days. The tissue specimens
were stained with an anti.PCNA antibody. The glomeruli of control rats
do not contain an appreciable number of the inimunostains (A, X 100).
The glomeruli of anti-Thy 1.1-injected rats contain a large number of the
immunostains at five days after injection of the antibody, while a marked
extent of cell proliferation is evident at day 5 after disease induction (B, ><
100). Expression of PCNA is diminished at the 14th day (C, x 100).
Fig. 6. Expression of brain-type myosin in normal and diseased glomeruli.
Rats were injected with anti-Thy 1.1 antibody, and the kidneys were
removed at the indicated days. The tissue specimens were stained with
anti-brain-type MHC antibody HBM1. Whereas the tissue specimen from
a control rat contains a significant level of the immunostains in the tubular
regions, the glomerular regions do not contain an appreciable level of the
immunostains (A, x 200). At five days after injection of anti-Thy 1.1, the
numbers of the mesangial cells are increased in most of the glomeruli,
while the brain-type myosin is only expressed slightly in the glomeruli (B,
X 200). At 10 days after anti-Thy 1.1 injection, the brain-type myosin is
expressed in the glomeruli in a readily detectable amount (C, x 200).
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Fig. 7. Immunoblot analysis of MHC isofarms in the glamendi of anti-Thy
1.1 GNrats. Rats were injected with anti-Thy 1.1 antibody, and the kidneys
were removed at the indicated days (0 to 14 days) and donated for the
preparation of glomeruli. Crude myosin extracts (30 jig protein/lane)
prepared from the glomeruli (dO-d14) and rat cerebellum (CL) were
subjected to SDS-PAGE and immunoblotting with an anti-smooth muscle,
nonmuscle and brain-type MHC antibody BBM4 (A) or with an anti-brain-
type MHC antibody HBM1 (B).
Fig. 8. Time courses of expressions of MJIB2 isoform (•) and PCNA (A,l in
the renal tissues of anti-Thy 1.1. GN rats. (A) Rats were injected with
anti-Thy 1.1 antibody, and the kidneys were removed at the indicated days.
Crude myosin extracts were prepared from the isolated glomeruli, and the
concentrations of the MIIB2 isoform in the extracts (10 jig protein) were
determined by ELISA on a plate coated with anti-brain-type MHC
antibody HBM1, as described previously [5, 6, 34]. Expression of PCNA in
the glomeruli of anti-Thy 1.1-injected rats was determined by the histo-
chemical and immunohistochemical procedures shown in Figures 4 and 5,
respectively. PCNA-expression is expressed by the labeling index, the
percentage of immunochemically stained nuclei per total nuclei. The
points and bars represent the mean values (N = 4) and sos, respectively.(B) A calibration curve for brain-type myosin with a best fit line (r2 =
0.994) determined by ELISA.
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appears to be delayed by approximately or more than five days
from that of PCNA (Fig. 8).
Discussion
The mesangial cells have been reported to contain fairly high
concentrations of both myosin and actin [27], cytoskeletal ele-
ments essential for cell motility [28], and these contractile proteins
are believed to be involved in the regulation of glomerular
filtration rate (OFR) by modulating the glomerular capillary
filtrating surface area [29]. A previous observation that the myosin
in cultured mesangial cells undergoes rapid phosphorylation in
response to several agonists such as arginine vasopressin, angio-
tensin II, and endothelin appeared to reinforce the role of myosin
in regulating the cell motility [2]. In addition to this function, the
myosin is likely to play a role in cellular proliferation, since
nonmuscle-type myosin has been shown to be involved in the
cellular proliferation, especially in the process of cytokinesis
[30—32]. A previous study has shown that the content of myosin
was increased in the mesangial cells of such glomerular diseases as
diabetic nephropathy [33], while it is not known with which
changes of the cellular functions the increased content of myosin
is related, the contractile activity or the proliferation of the cells.
In the present study, we have shown that nearly all of the patients
with proliferative ON contain increased concentrations of a
brain-type myosin isoform in the mesangial cells and that normal
rats increase the contents of the brain/embryo-type myosin iso-
form (MIIB2) in the mesangial cells by injecting the anti-Thy 1.1
antibody. Althogh much of the brain-type myosin isoform expres-
sion does appear to be mesangial cells in Figure 3 A and B, and
Figure 6C, it is possible that some of the myosin expression may
be originating from other cells within glomerulus, such as the
endothelial cell or podocyte. While we were unable to determine
which type of the two brain isoforms was expressed in the
mesangial cells from patients with proliferative ON, MIIB1 or
MIIB2, because of the limitation of the amounts of the biopy
samples, the MHC expressed in these cells was likely to be mostly
the MIIB2 isoform. These results indicate that the expression of
the brain/embryo-type isoform is accelerated with development
or/and progression of proliferative GN, although the reason for
the increased expression of the isoform is not known. It is unlikely,
however, that the increased expression of the myosin isoform is
prerequisite to the proliferation of the mcsangial cells, since (1)
the expression of the isoform is induced after the expression of
PCNA was almost completed (Figs. 5, 6 and 8), and (2) most of
the human tissue specimens from proliferative ON did not contain
a significant level of PCNA. Thus these facts are remarkably
contrastive with the previous report that the expression of
a-smooth muscle actin is associated with the expression of PCNA
in mesangial cells in biopsy specimens from patients with ON and
in rat Thy 1.1 ON [17, 18]. Therefore, it is likely that the
brain/embryo-type isoform plays a role in the process different
from the a-smooth muscle actin in ON. The result shown in
Figure 8 also indicated that the content of the nonmuscle myosin
(MIIA) was increased slightly together with the MIIB2 isoform in
the rat model of ON. The increased expression of the MIIA
isoform does not appear to be prerequisite to the proliferation of
the mesangial cells, although this result does not exclude the
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possibility that the pre-existed isoform is involved in cellular
division [30—321.
Recently, we have found that regenerating rat hepatic tissues
also express an increased level of the brain/embryo-type MHC
isoform for a short period after partial hepatectomy [34]. The
level of the MHC isoform was highest at a few days after the peak
of the expression of PCNA was attained, as in the experimental
ON. The MIIB2 isoform appeared to diminish with recoveries of
both the size and function of the tissues, as estimated from the
tissue weight and the serine dehydratase activity, respectively [34].
The result shown in Figure 8 also indicates that the anti-Thy
1.1-induced brain/embryo-type myosin gradually decreases its
level toward the basal level with the recovery from the nephritis,
as estimated from the morphological integrity of the tissues (not
shown) [20]. On the other hand, nearly all of the renal tissues from
patients with chronic proliferative ON were found to continuously
contain significant levels of the isoform in the glomeruli. Whereas
the reason for the successive presence of this isoform is not
known, it is likely to reflect the fact that mesangial cells of GN
exhibit a different phenotype from the normal cells. Although the
changes in the isoform mentioned above were observed under
rather specialized tissue conditions, partial hepatectomy and
experimental and chronic GN, a limited number of normal adult
tissues also contain varied but nearly fixed levels of the isoform.
Brain tissues contain fairly high concentrations of the isoform and
the renal tissues contain a small concentration of the isoform in
the tubular cells. It is also evident that many fetal tissues such as
liver, thymus, skeletal and cardiac muscle and arteries contain
each a fairly high concentration of the isoform [10, 12]. These
facts appear to suggest that the brain/embryo-type MHC isoform
is involved in some process(es) that are necessary to maintain the
tissues in such a specialized physiological state as in diseases and
in embryo or fetus.
It has been shown recently that the development of atheroscle-
rosis is accompanied by changes in the MHC isoforms character-
ized by the increase in the level of the brain/embryo-type MHC
isoform MIIB2 and the decrease in the levels of the smooth
muscle MHC isoforms, SM1 and SM2. These changes have been
proposed to be involved in the phenotypic transformations of the
muscle cell from a contractile form to a synthetic form [12, 13, 35J.
On the other hand, it has also been shown that brain myosins
(MIIB1 and MIIB2) exhibit a considerable magnitude of contrac-
tile activity in vitro in response to phosphorylation by Ca27
calmodulin-dependent myosin light chain kinase [36]. Further-
more, these myosins possess different physical and enzymatic
properties from those of smooth muscle and other nonmuscle
myosins. The filaments of unphosphorylated brain myosin are not
dissociable in the presence of ATP or 0.3 M KC1, while those of
smooth muscle and nonmuscle myosins were dissociated under
the same conditions [37]. Although the mechanisms by which the
brain/embryo-type myosin participates in phenotypic transforma-
tions of the mesangial cells is not known, the isoform may play a
role in providing the cells with a specialized type of cellular
motility occurring in ON.
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